Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases

Current Opinion in Pharmacology

Volumn 8, Issue 1, 2008, Pages 8-13

  Marsh, Brenda J ^a   Stenzel Poore, Mary P ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; IMIQUIMOD; LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DRUG TARGETING; GENETIC CONSERVATION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROKE; TISSUE INJURY; TUMOR IMMUNITY;

ANIMALS; BRAIN DISEASES; HUMANS; IMMUNE TOLERANCE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 38749121741     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.09.009     Document Type: Review

References (40)

1. Prins R.M., Craft N., Bruhn K.W., Khan-Farooqi H., Koya R.C., Stripecke R., Miller J.F., and Liau L.M. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176 (2006) 157-164
2. Won E.K., Zahner M.C., Grant E.A., Gore P., and Chicoine M.R. Analysis of the antitumoral mechanisms of lipopolysaccharide against glioblastoma multiforme. Anticancer Drugs 14 (2003) 457-466
3. Chicoine M.R., Zahner M., Won E.K., Kalra R.R., Kitamura T., Perry A., and Higashikubo R. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 60 (2007) 372-380 discussion 381
4. Carpentier A.F., Chen L., Maltonti F., and Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59 (1999) 5429-5432
5. Auf G., Carpentier A.F., Chen L., Le Clanche C., and Delattre J.Y. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 7 (2001) 3540-3543
6. El Andaloussi A., Sonabend A.M., Han Y., and Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54 (2006) 526-535
7. Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., and Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8 (2006) 261-279
8. Meng Y., Carpentier A.F., Chen L., Boisserie G., Simon J.M., Mazeron J.J., and Delattre J.Y. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116 (2005) 992-997
9. Carpentier A., Laigle-Donadey F., Zohar S., Capelle L., Behin A., Tibi A., Martin-Duverneuil N., Sanson M., Lacomblez L., Taillibert S., et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8 (2006) 60-66. A Phase 1 clinical trial to define the safety profile of CpG-28, administered intratumorally to patients with recurrent glioblastoma.
10. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995. A review of TLR expression and function in cells of the innate and adaptive immune systems.
11. Tasaki K., Ruetzler C.A., Ohtsuki T., Martin D., Nawashiro H., and Hallenbeck J.M. Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats. Brain Res 748 (1997) 267-270
12. Rosenzweig H.L., Lessov N.S., Henshall D.C., Minami M., Simon R.P., and Stenzel-Poore M.P. Endotoxin preconditioning prevents the cellular inflammatory response during ischemic neuroprotection in mice. Stroke 35 (2004) 2576-2581
13. Hickey E.J., You X., Kaimaktchiev V., Stenzel-Poore M., and Ungerleider R.M. Lipopolysaccharide preconditioning induces robust protection against brain injury resulting from deep hypothermic circulatory arrest. J Thorac Cardiovasc Surg 133 (2007) 1588-1596
14. Bordet R., Deplanque D., Maboudou P., Puisieux F., Pu Q., Robin E., Martin A., Bastide M., Leys D., Lhermitte M., et al. Increase in endogenous brain superoxide dismutase as a potential mechanism of lipopolysaccharide-induced brain ischemic tolerance. J Cereb Blood Flow Metab 20 (2000) 1190-1196
15. Rosenzweig H.L., Minami M., Lessov N.S., Coste S.C., Stevens S.L., Henshall D.C., Meller R., Simon R.P., and Stenzel-Poore M.P. Endotoxin preconditioning protects against the cytotoxic effects of TNFa after stroke: a novel role for TNFa in LPS-ischemic tolerance. On line publication. J Cereb Blood Flow Metab (2007). The authors demonstrate that LPS pretreatment protects the brain from the injurious effects of ischemia-induced TNFα.
16. Kunz A., Park L., Abe T., Gallo E.F., Anrather J., Zhou P., and Iadecola C. Neurovascular protection by ischemic tolerance: role of nitric oxide and reactive oxygen species. J Neurosci 27 (2007) 7083-7093
17. Dawson D.A., Furuya K., Gotoh J., Nakao Y., and Hallenbeck J.M. Cerebrovascular hemodynamics and ischemic tolerance: lipopolysaccharide-induced resistance to focal cerebral ischemia is not due to changes in severity of the initial ischemic insult, but is associated with preservation of microvascular perfusion. J Cereb Blood Flow Metab 19 (1999) 616-623
18. Bastide M., Gele P., Petrault O., Pu Q., Caliz A., Robin E., Deplanque D., Duriez P., and Bordet R. Delayed cerebrovascular protective effect of lipopolysaccharide in parallel to brain ischemic tolerance. J Cereb Blood Flow Metab 23 (2003) 399-405
19. Ginis I., Schweizer U., Brenner M., Liu J., Azzam N., Spatz M., and Hallenbeck J. TNF-alpha pretreatment prevents subsequent activation of cultured brain cells with TNF-alpha and hypoxia via ceramide. Am J Physiol 276 (1999) C1171
20. Ziegler G., Harhausen D., Schepers C., Hoffmann O., Rohr C., Prinz V., Konig J., Lehrach H., Nietfeld W., and Trendelenburg G. TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 359 (2007) 574-579
21. Cao C.X., Yang Q.W., Lv F.L., Cui J., Fu H.B., and Wang J.Z. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun 353 (2007) 509-514. The authors implicate endogenous TLR4 signaling in the exacerbation of cerebral ischemic damage.
22. Kinouchi H., Sharp F.R., Hill M.P., Koistinaho J., Sagar S.M., and Chan P.H. Induction of 70-kDa heat shock protein and hsp70 mRNA following transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 13 (1993) 105-115
23. Medvedev A.E., Lentschat A., Wahl L.M., Golenbock D.T., and Vogel S.N. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase1 activation in endotoxin-tolerant cells. J Immunol 169 (2002) 5209-5216
24. Sly L.M., Rauh M.J., Kalesnikoff J., Song C.H., and Krystal G. LPS-induced upregualtion of SHIP is essential for endotoxin tolerance. Immunity 21 (2004) 227-239
25. Kobayashi K., Hernandex L., Galan J.C.A., Janeway J., Medzhitov R., and Flavell R. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110 (2002) 191-202
26. Broad A., Kirby J.A., and Jones D.E. Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production. Immunology 120 (2007) 103-111. The authors demonstrate a shift in TLR4 signaling, away from the MyD88 dependent pathway towards the MyD88 independent pathway, in endotoxin-tolerant cells.
27. Yamamoto M., Sato S., Mori K., Hoshino K., Takeuchi O., Takeda K., and Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol 169 (2002) 6668-6672
28. Kariko K., Ni H., Capodici J., Lamphier M., and Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279 (2004) 12542-12550
29. Bsibsi M., Ravid R., Gveric D., and Noort JMv. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61 (2002) 1013-1021
30. Lafon M., Megret F., Lafage M., and Prehaud C. The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci 29 (2006) 185-194
31. Farina C., Krumbholz M., Giese T., Hartmann G., Aloisi F., and Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 159 (2005) 12-19
32. Olson J.K., and Miller S.D. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173 (2004) 3916-3924
33. Krasowska-Zoladek A., Banaszewska M., Kraszpulski M., and Konat G.W. Kinetics of inflammatory response of astrocytes induced by TLR 3 and TLR4 ligation. J Neurosci Res 85 (2007) 205-212
34. Veldhuis W.B., Floris S., van der Meide P.H., Vos I.M., de Vries H.E., Dijkstra C.D., Bar P.R., and Nicolay K. Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption. J Cereb Blood Flow Metab 23 (2003) 1060-1069. The authors show that direct IFNβ administration maintains the integrity of the blood-brain barrier after ischemic insult and reduces inflammatory cell infiltration.
35. Veldhuis W., Derksen J., Floris S., van der Meide P., de Vries H., Schepers J., Vos I., Dijkstra C., Kappelle L., Nicolay K., et al. Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat. J Cereb Blood Flow Metab 23 (2003) 1029-1039
36. Liu H., Xin L., Chan B.P.L., Teoh R., Tang B.L., and Tan Y.H. Interferon beta administration confers a beneficial outcome in a rabbit model of thromboembolic cerebral ischemia. Neurosci Lett 327 (2002) 146-148
37. Bsibsi M., Persoon-Deen C., Verwer R.W., Meeuwsen S., Ravid R., and Van Noort J.M. Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators. Glia 53 (2006) 688-695. The authors show that astrocytes produce neuroprotective molecules in response to Poly(I:C) administration which enhance neuronal survival in human brain slice cultures.
38. Scumpia P.O., Kelly K.M., Reeves W.H., and Stevens B.R. Double-stranded RNA signals antiviral and inflammatory programs and dysfunctional glutamate transport in TLR3-expressing astrocytes. Glia 52 (2005) 153-162
39. Newman M.F., Kirchner J.L., Phillips-Bute B., Gaver V., Grocott H., Jones R.H., Mark D.B., Reves J.G., and Blumenthal J.A. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N Engl J Med 344 (2001) 395-402
40. Selim M. Perioperative stroke. N Engl J Med 356 (2007) 706-713. A clinical review of the pathophysiology of perioperative stroke with emphasis on risk stratification, risk modification, and patient management.